Results 41 to 50 of about 2,631,955 (205)

Correlation of events and neoepitopes with the tumor mutation burden.

, 2021
(A) Correlations between the number of splicing alterations detected and the tumor mutation burden (TMB) for all the SCLC patients, separated by splicing alteration type.
Judith Pérez-Granado (11442479), Juan L. Trincado (11442473), Ferran Sanz (89706), Marina Reixachs-Solé (11442476), Tim Fugmann (11442482), Eduardo Eyras (3024), Jun Yokota (133873)   +6 more
core   +1 more source

Panels and models for accurate prediction of tumor mutation burden in tumor samples

npj Precision Oncology, 2021
Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the ...
Elizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje   +2 more
doaj   +1 more source

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer

Frontiers in Oncology, 2021
ObjectiveTo explore the mutated genes in esophageal cancer (ESCA), and evaluate its relationship with tumor mutation burden (TMB) and prognosis of ESCA, and analyze the advantages of FAT3 as a potential prognostic marker in ESCA.MethodsThe somatic ...
Zixin Guo, Zixin Guo, Xin Yan, Xin Yan, Congkuan Song, Congkuan Song, Qingwen Wang, Qingwen Wang, Yujin Wang, Yujin Wang, Xiao-Ping Liu, Jingyu Huang, Jingyu Huang, Sheng Li, Sheng Li, Weidong Hu, Weidong Hu   +16 more
doaj   +1 more source

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

npj Precision Oncology, 2021
With the recent FDA approval of tumor mutational burden-high (TMB-H) status as a biomarker for treatment with a PD-1 inhibitor regardless of tumor type, accurate assessment of patient-specific TMB is more critical now more than ever.
Yan W. Asmann, Kaushal Parikh, P. Leif Bergsagel, Haidong Dong, Alex A. Adjei, Mitesh J. Borad, Aaron S. Mansfield   +6 more
doaj   +1 more source

Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing

Cancer Cell International, 2021
Objective To investigate the genetic prognostic factors for the recurrence of non-muscle invasive bladder cancer. Materials and methods The patients underwent transurethral resection of bladder tumor and received bacillus Calmette–Guérin (BCG) or ...
Yanxiang Shao, Xu Hu, Zhen Yang, Thongher Lia, Weixiao Yang, Kan Wu, Shangqing Ren, Sanchao Xiong, Weichao Dou, Shuyang Feng, Yaohui Wang, Yang Liu, Kang Wu, Xiang Li   +13 more
doaj   +1 more source

Fusobacterium Nucleatum-Induced Tumor Mutation Burden Predicts Poor Survival of Gastric Cancer Patients

, 2022
Co-infection of Helicobacter pylori and Fusobacterium nucleatum is a microbial biomarker for poor prognosis of gastric cancer patients. Fusobacterium nucleatum is associated with microsatellite instability and the accumulation of mutations in colorectal ...
Chin Li, Yung-Yu Hsieh, Wen-Lin Kuo, Shui-Yi Tung, Wan-Ting Hsu   +4 more
core   +1 more source

Tumor mutational burden is not predictive of cytotoxic chemotherapy response [PDF]

OncoImmunology, 2020
High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic ...
Mina Nikanjam, Paul Riviere, Aaron Goodman, Donald A. Barkauskas, Garrett Frampton, Razelle Kurzrock   +5 more
openaire   +5 more sources

Supplementary Table 1 from Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

, 2019
Tumor mutation burden in MSI-H ...
Seung-Yong Jeong (414029), Hoon Jang (760001), Hyoki Kim (715590), Duhee Bang (736906), Sae-Won Han (15015668), Kyu Joo Park (9642105), Jeong Mo Bae (15015671), Dae-Won Lee (706990), Gyeong Hoon Kang (15015677), Hyojun Han (15015674), Tae-You Kim (73316)   +10 more
core   +1 more source

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

Scientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby, Ernest Bognar, Laura Stanbery, Casey Nagel, Gladice Wallraven, Aman Pruthi, Nicholas Bild, Ericca Stamper, Donald Rao, Adam Walter, John Nemunaitis   +10 more
doaj   +1 more source

Supplementary Figure 1 from Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

, 2019
Prognostic role of tumor mutation burden (TMB) stratified by microsatellite instability (MSI) status.
Seung-Yong Jeong (414029), Hoon Jang (760001), Hyoki Kim (715590), Duhee Bang (736906), Sae-Won Han (15015668), Kyu Joo Park (9642105), Jeong Mo Bae (15015671), Dae-Won Lee (706990), Gyeong Hoon Kang (15015677), Hyojun Han (15015674), Tae-You Kim (73316)   +10 more
core   +1 more source